Introduction
============

The complex and dynamic biological process of healing following an injury is linked to the activation of coagulation and of the immune system ([@B117]; [@B209]). Indeed, reparative processes can functionally restore endothelial integrity after a damage (infectious, post-traumatic, shear stress-induced, or metabolic-related) and hereafter activate the immune system ([@B143]; [@B117]). Activation of these integrated processes relies upon cellular components and circulating factors that are crucial to stimulate physiological repair and tissue rearrangement, and essential to the homeostasis of central nervous system (CNS) ([@B45]).

The paramount step to secure the integrity of the system is the scouting of the endothelial damage and the clot formation. The coagulation players have been divided into cellular and protease components, the latter playing into three pathways: intrinsic, extrinsic, and common ([@B126]). In this review the clotting factors will be addressed with Roman numbers, with the post-position of the letter "a" to indicate the activated factor ([@B69]) except for the FI-IV that will be addressed as fibrinogen, prothrombin, tissue factors (TFs) and Calcium (Ca^2+^) (Table [1](#T1){ref-type="table"}).

###### 

List of the coagulation factors with their assigned Roman numbers and the alternative names that are found in the literature.

  Factor number   Alternative name(s)
  --------------- --------------------------------------------
  I               Fibrinogen (fibrin zymogen)
  II              Prothrombin (thrombin zymogen)
  III             Tissue factor
  IV              Calcium
  V               Labile factor, proaccelerin
  VI              Unassigned (previously activated factor V)
  VII             Stable factor (proconvertin)
  VIII            Antihemophilic factor A
  IX              Christmas factor, antihemophilic factor B
  X               Stuart prowar factor
  XI              Plasma thromboplastin antecedent
  XII             Hageman factor
  XIII            Fibrin stabilizing factor

The explorers of damage are FVII (described as the extrinsic pathway initiator), the only human factor circulating as both FVII and FVIIa to monitor TF exposure, and FXII (the intrinsic pathway initiator), whose activation is induced by subendothelial collagen in the presence of high-molecular-weight kininogen (HMWK). The TF-FVIIa complex activates FIX and FX, while FXIIa activates FXI, which also leads to FIXa. FXa indeed converts low levels of prothrombin in thrombin ([@B192]). Briefly, low concentration of thrombin and FXa are the scouting signals that can either trigger the amplification or be neutralized by the surrounding healthy cells.

Platelet are then activated with the formation of pseudopodia that allow covering the injury site and the release of granular (α and δ granules) mediators ([@B117]). In fact, once the damage has been localized, degranulation of α-granules exposes P-selectin, activates integrin αIIbβ3, promotes circulating immune cells adhesion and releases fibrinogen, VWF, FV and more than 300 proteins, including chemokines ([@B7]) and growth factors, such as platelet-derived growth factor (PDGF), brain-derived neurotrophic factor (BDNF), fibroblast growth factor (FGF), and the vascular endothelial growth factor (VEGF) ([@B143]; [@B30]). P-selectin, also known as Cluster of Differentiation (CD)62P, and glycoprotein (GP)Ib on platelets are respectively recognized on white cells by P-selectin glycoprotein ligand 1 (PSGL1) and αMβ2 integrin CD11b/CD18, also known as Macrophage-1 antigen (Mac-1) or CR3, the latter able to bind also complement, fibrinogen and platelet GPIIb-IIIa ([@B143]; [@B117]). Chemokines, or chemotactic cytokines, are classified into families according to the arrangement of the cysteine residues that constitutes the disulfide bridges, namely CXCL, CC, CX3C, XC ([@B223], [@B224]). Among chemokines, platelet factor 4 (PF4, also known as CXCL4), CXCL1, interleukin-8 (IL-8) ([@B7]) and CXCL7 are absolutely the most abundant, the latter used as a marker of megakaryocytic lineage. However, several other molecules (CCL5, CXCL5, CXCL12) have been recognized, and there is evidence of distinct and specialized α-granules subclasses containing subsets of chemokines specifically released under certain pathophysiological conditions ([@B80]; [@B202]).

The δ granules (or dense granules) release bioactive amines (e.g., histamine and serotonin), adenine nucleotides (ADP, ATP, and cAMP), poly- and pyrophosphates, and high concentrations of cations, above all Ca^2+^ ([@B7]). A high local concentration of FXa and thrombin ends the amplification phase and induces its propagation and the last proteolytic cleavage that involves fibrinogen, which is then transformed into fibrin and stabilized by the transglutaminase FXIIIa. Plasminogen, activated by tissue-type plasminogen activator (tPA) into the protease plasmin, can ultimately disassemble the fibrin aggregates ([@B137]). Moreover, thrombin on the intact vessel wall can inhibit itself: it binds to thrombomodulin and cleaves Protein C (PC) into its activated form (aPC) which, together with Protein S and TFPI, inactivates FVa, FVIIIa and inhibits FXa, thus limiting and quenching the process ([@B155]; [@B133]).

Moreover, on cell surface thrombin can trigger the complement cascade ([@B73]). Activated complement receptor (CR)2 is present on resting platelets expressing GPIb, as well as the iC3b binding on CR3, while C3a, C5a (the so-called anaphylatoxin) and C4a are bound on human platelets ([@B36]). However, to inhibit spontaneous aggregation and membrane attack complex (MAC) formation, it is pivotal the expression of Factor H (FH) and thrombospondin type 1 (TSP-1) ([@B129]). The important regulation of this system has been demonstrated, for example, in the atypical hemolytic uremic syndrome (aHUS), where the deficit of FH (genetic or acquired) causes the triad: anemia, thrombocytopenia, and uremia (due to acute renal failure) ([@B85]).

Neuro-Immune Hemostasis and Neuroinflammation
=============================================

The complexity of the neuro-immune system interaction starts at the level of the neurovascular unit. This structure is composed by the blood--brain barrier (BBB) elements (endothelial cells, pericytes and the astrocytic foot endings) on the one side, and neurons, glia and extracellular matrix (ECM) on the other side ([@B134]). All together, these elements (neurons, glia, and ECM) constitute what has been well-described as the tetrapartite synapse ([@B48]; [@B200]; [@B43], [@B44]).

This complex structure accounts for the immune privileged properties of the brain and of the spinal cord (which has its own blood--barrier BSCB) ([@B11]). The efficacy of the barrier is based on the innate immune properties of resident cells (neurons and glia), which interact with pathogens, endogenous (e.g., unfolded or misfolded proteins) or exogenous toxins, to maximize the adaptive response and to reduce the collateral damage ([@B127]; [@B91]). The resiliency of the system strictly depends on a variety of proteins that have been grouped for their functional role of neuro-immune regulators (NIReg) and are expressed on both glial cells and neurons ([@B13]).

NIReg are constitutively expressed on neurons and acts as "Don't eat me" signals for microglial cells that are maintained in a resting state (such as the CD200, CD47, and CXCL1), or they negatively regulate complement activation (CD59, CD46, FH) ([@B13]) (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Moreover, resident cells are able to repress deregulated cytokine activation through the expression of Suppressor Of Cytokine Signaling (SOCS) that interferes with the inflammatory-related activation of the JAnus-Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) intracellular polarizing pathway ([@B13]).

![Molecular pathways of the neuro-immune hemostasis model. Cytokine activation of JAK-STAT tyrosine kinase receptor can be turned off by SOCS expression and, together with the complement regulation and the biased activation of PAR-1/β arrestin (β arr2) (orange pathway), they enhance the adaptive response. The canonical activation of PAR1, together with tyrosine kinase receptor activation and the fibrin deposition (blue pathway), accelerate maladaptive cellular changes.](fncel-12-00459-g001){#F1}

Thrombin, a crucial protein in this network, has been reported to affect the behavior of CNS resident cells, such as neurons ([@B145]), astrocytes and microglia ([@B99]; [@B14]) in a dose dependent manner, with adaptive changes at low dose and maladaptive modifications at high concentration.

Of relevance for thrombin interaction with CNS resident cells, endothelium, and immune cells, is the proteinase activated receptor (PAR) family, G protein coupled receptors (GPCR)s with four recognized members (PAR1-4). PARs can be activated by a proteolytic cleavage of the extracellular amino-terminal domain of their seven-transmembrane α-helix structure ([@B84]; [@B211]; [@B109]; [@B198]; [@B203]). Thrombin (not complexed with thrombomodulin), FXa, plasmin, and matrix metalloproteinases-1 (MMP-1) canonically activate PAR1 on cell surface, unmasking the tethered ligand with a proteolytic cleavage and causing its internalization ([@B218]; [@B213]). Thrombin can alter neuronal viability through PAR-1 interaction, since thrombin antagonists and pharmacological/genetic PAR-1 inhibitors increase neuroprotection ([@B159]). PAR2, instead, can be activated by low-concentration of trypsin. PAR3 is the only PAR with no function because of its short cytoplasmic domain ([@B38]). Indeed, it can act as a cofactor for other PARs to form heterodimers and amplify the variety of intracellular transduction systems ([@B6]; [@B100]), perhaps by allosteric modification and interaction with different G proteins (Gαq/11, Gαi/o, Gα12/13) ([@B147]; [@B125]). Non-canonical cleavage by aPC also activates PAR1 (biased agonism) and trigger a different intracellular pathway (Figure [1](#F1){ref-type="fig"}). The aPC binds to the coreceptor endothelial PC receptor (EPCR) and cleaves PAR1 ([@B164]), but does not induce its internalization as being co-localized in caveolin-rich membrane domains ([@B166]). Canonical-cleavage activates Guanosine-triphosphatase (GTPase) rat-sarcoma protein (Ras)-related protein-A (RhoA), while non-canonical cleavage (aPC-mediated) stimulates GTPase Ras-related C3-botulinum toxin substrate-1 (Rac1) through β arrestin (βarr2) and disheveled 2 (Dvl-2), usually associated to frizzled receptors (FZD) ([@B166]; [@B181]). Moreover, C4a has been proposed as an untethered agonist for PAR1 and PAR4 acting through Gαq-Phospholipase C (PLC) pathway that within nanomolar concentrations can cause intracellular Ca^2+^ release ([@B209]) (Figure [1](#F1){ref-type="fig"}).

NIReg also include serpins and thrombomodulin, which are able to reduce the potential neurotoxicity of thrombin, mainly mediated through tethered ligand activation of PAR1 signaling ([@B24]; [@B142]) (Figure [1](#F1){ref-type="fig"}). The lipopolysaccharide (LPS), furthermore, stimulates the expression of coagulation and inflammation factors in the hippocampal microglia, but a sharp reduction of both inflammatory and coagulation factors occurs when the thrombin-mediated signal is inhibited ([@B178]).

Definitely, based on relevance of the neurovascular unit in modulating neuro-immune hemostasis and neuroinflammation, we propose that the neurovascular complex can be associated with the tetrapartite synapse to form an ultimately unified pentapartite synaptic model (Figure [2](#F2){ref-type="fig"}). This model might better represent the complex and robust interplay between cellular and molecular pathways of coagulation and the immune system, as reported by *in vitro* or *in vivo* studies ([@B197]; [@B10]). The analysis of the state of the art in this field can partly reveal the pathophysiology of neuro-inflammatory and neurodegenerative diseases, such as multiple sclerosis (MS), cerebrovascular, Alzheimer, neoplastic and psychiatric diseases.

Multiple Sclerosis
==================

Multiple sclerosis is a demyelinating autoimmune inflammatory disease affecting the CNS white matter. It lacks a commonly recognized causative agent (idiopathic), and the multifactorial interactions between environment and genetics are not fully elucidated ([@B171]; [@B15]). Though the pathophysiology of MS remains unknown, there is morphological evidence of its inflammatory origin and of the resulting neurodegeneration, moreover, therapies targeting the inflammasome modify the progression of the disease (mainly the relapsing-remitting phenotype) ([@B40]).

On the base of the clinical observation and the progression, MS can be classified into two forms, relapsing-remitting and progressive (primary or secondary) ([@B108]). Inflammation with relatively preserved cell viability seems to be the hallmark of relapsing-remitting early stages, is characterized by clinical features that can affect the motor system (particularly the pyramidal tract) or non-motor areas, depending on which part of the CNS is affected by the demyelination. Every relapse is followed by a spontaneous partial remission, ameliorated by early therapy ([@B108]), while the progressive forms, either the primary or the evolution of the initially relapsing-remitting MS (secondary), are characterized by a continuous neurodegeneration with almost ineffective therapy on its progression ([@B108]; [@B58]).

Which is the key to understand the failure of the immune system has been long debated. Inflammatory autoimmunity, defined "horror autotoxicus" by Paul Ehrlich over a century ago ([@B53]), starts with the erroneous recognition of an endogenous target as a threat, with the activation of resident cells that present it to the immunity effectors. As discussed above, the neurovascular unit should prevent inappropriate migration of leukocytes from the bloodstream and protect the CNS. The Trojan horse that could cause the BBB failure and allow the specific T-cells diapedesis has not been identified yet, but a putative role could be assigned to platelets activation and fibrin depots in the CNS and other tissues ([@B78]; [@B82]). These cellular and protein aggregates can be produced by a minimal vascular damage or venous stasis, and their pathological accumulation could produce a non-diffusible and localized signal to mediate lymphocyte T helper (Th)1 migration and myelin targeting ([@B167]). This hypothesis is supported by the evidence of the occurrence of fibrinogen in myelinated areas that correlates with T-cells invasion and IL-12 mediated Th1 differentiation, macrophage activation through CCL2 and CXCL10 and following demyelination ([@B105]). Antibodies directed to GPIb or GPIIb-IIIa reduce the severity of the disease in an animal model, whereas increased integrin αIIb gene (ITGA2B) mRNA has been found in chronic lesions of MS patients ([@B104]; [@B92]). Furthermore, in the autoimmune encephalomyelitis model (EAE) it has been shown that depletion of fibrinogen blocks T-cell activation, accelerating the coagulopathy-mediated pathway ([@B3]), where the presence of fibrin or platelets are the erroneous triggering signal, allowing antigen presenting cells to interact with lymphocytes and delete the immune privilege property of the CNS ([@B105]). Thrombin, in addition, can speed the process between platelet activation and fibrin deposition (Figure [1](#F1){ref-type="fig"}) favoring the formation of aggregates, and drive the leukocytes through release of granular CCL3, CCL5, PF4 (CXCL4), and CXCL5 ([@B161]).

Platelet activation is associated with clinically assessed worsening of MS, as demonstrated by the positive correlation between the Expanded Disability Status Scale (EDSS) and the level of Cyclooxygenase (COX)-1 activity, and the levels of the eicosanoid thromboxane B2 (TBX2) in blood platelets of MS patients ([@B130]). Furthermore, mediators from platelet granules include growth factors (i.e., BDNF) and chemokines involved, together with MMPs, in both hemostasis and inflammatory progression ([@B131]). Hence, the initial vascular damage activates platelets and converts fibrinogen. Platelets phenotype, at this point, is characterized by low selectin expression and low-rate degranulation. The granule content (PF4, serotonin, chemokines, cytokines, ADP, ATP, etc.) is released more efficiently upon contact with astrocytes, neuronal glycolipids and ECM ([@B182]) (Figure [2](#F2){ref-type="fig"}). The acute inflammatory response is not produced only by the active degranulation; the expression of other proteins is needed to activate the inflammasome. One of the main proteins involved, and utterly the most studied, is Interleukin-1β (IL-1β) synthesized on demand from a messenger RNA stored inside platelets. IL-1β is secreted and found in occlusive thrombi after vascular damage (before leukocyte incorporation) ([@B117]). Moreover, the corresponding receptor (IL1R) is expressed on the platelet surface, allowing an autocrine self-sustaining feedback ([@B22]). Tumor necrosis factor-α (TNF-α) also seems to be influenced by platelets activation, since its depletion significantly reduces white cells diapedesis during TNFα-mediated CNS phlogosis ([@B28]). TNF-α can induce cellular apoptosis or contribute to chemokine generation and neurodegeneration through necroptosis ([@B47]).

![Cellular model of a pentapartite synapse. Common cellular pathways and cell-specific role within the neuro-immune hemostasis network.](fncel-12-00459-g002){#F2}

This unregulated process induces BBB leakage, antigen presentation, activation of CD4 positive T-cells and their differentiation into Th1 or Th17 ([@B184]). During later stages, the process is self-sustaining and platelets change their phenotype, express a higher level of selectins and adhere to T-cells or to antigen presenting cells, forming aggregates ([@B184]).

The pivotal role of the molecular components of the coagulation cascade is confirmed by the protective action in the EAE model exerted by the administration of both warfarin and the non-vitamin K antagonist oral anticoagulant (NOAC) rivaroxaban (direct inhibitor of FXa) ([@B187]). Thrombin can interrupt BBB integrity through PAR1 signaling; however, warfarin effect seems to be greater than rivaroxaban, probably resulting for the interactions with other proteins of the coagulation pathway, such as FVII ([@B37], [@B38]). The lysis of fibrin, furthermore, should inhibit microglia activation via CD11b (part of CR3, encoded by ITGAM gene) and produce a similar beneficial effect in the EAE model without the possible detrimental side effect of warfarin due to the inhibition of the aPC endothelial protective functions ([@B2]; [@B170]). The protective role of aPC, however, is not a linear process; it has been shown that the anticoagulant and the intracellular signaling function of aPC are both essential to exert neuroprotection. However, both the inhibition of the endogenous aPC and the administration of exogenous aPC ameliorated the EAE outcome ([@B4]). This seems apparently controversial, but it can be explained because reduced endogenous aPC can induce early leukocyte infiltration due to BBB instability; at the same time, it increases CD11b positive elements, interfering with T-cells differentiation, thus reducing disease progression ([@B4]). Reduction of aPC is effective only if it is induced before the disease onset ([@B4]).

As the aforementioned CD11b positive elements confirm, the complement system pathway is a prominent component of the immune response and is entirely involved in inflammatory autoimmune disease at various levels. The system plays a pivotal role in essentially all immune-mediated processes, and it made difficult, although intriguing, designing drugs targeting its components. Complement proteins can act through three main activation pathway: classical, lectin and alternative pathway, all at the end forming the MAC complex with the elimination of target cells ([@B76]). A coding variant in the C3 gene (C3R102G) reduced C3 activity and affected white/gray matter damage that is related to increased cognitive dysfunction in MS patients ([@B165]). Detrimental effects of complement interference can be overcome through inhibition at the lower level of complement activation cascade (e.g., C5). This strategy may reduce detrimental inflammation without affecting previous signaling steps. Hence, Eculizumab an inhibitor of C5, already approved for treatment of the paroxysmal---nocturnal hemoglobinuria (PNH), and of the aHUS ([@B120]; [@B33]) is undergoing phase III clinical trial for another autoimmune demyelinating disease of the CNS, the neuromyelitis optica (NMO) either for prevention or relapses forms^[1](#fn01){ref-type="fn"}^. NMO with dominant involvement of optic nerves and spinal cord has been previously considered as a variant of MS. Nowadays, it is considered a distinct disease ([@B199]) and even though it can lead to a more early disability, there are few approved therapeutic protocols ([@B199]). Furthermore, human post-mortem study has demonstrated that neurons from patients with progressive MS express a higher level of PAR1 and are exposed to granzyme B and IL-1β, inflammatory mediators that could at least partially explain by their neurotoxic effect the progressive related cortical atrophy ([@B95]).

Cerebrovascular Diseases
========================

The link between coagulation and cerebrovascular diseases seems causative, however, recent findings confirm the pivotal role of the coagulation/immune pathways during the plastic remodeling following or associated to the acute event. After an ischemic and hemorrhagic stroke, cortical synaptic remodeling is largely biased by a maladaptive response accounting for about 10% of epileptic seizures in elder ([@B115]; [@B157]; [@B72]). Moreover, the efficacy of thrombolysis and the current guidelines for the management of acute ischemic stroke (AIS) have rapidly reduced the acute mortality rate. Nowadays, the main social burdens and future challenges concern prolonged hospitalization, ineffective rehabilitation program, disability, and the epileptic sequelae ([@B191]; [@B25]; [@B201]; [@B66]). Studies on human platelet activation focused on platelet ultrastructure and plasma levels of PF4, thrombin--antithrombin complex, fibrinogen and other biomarkers in patients with AIS, and during the chronic phase or with atherosclerosis (without stroke) compared to healthy subjects ([@B90]). Data are compatible with platelet pre-activation in atherosclerotic patients, similar but lower compared to patients with AIS or chronic phase. Pre-activated platelets showed a higher density of pseudopods and vacuoles ([@B90], [@B89]). The endothelial damage reported in atherosclerosis, combined with a pre-activated state of platelets, is the most plausible factor for inflammatory-mediated CNS damage that accelerates the major hypoxic injury.

Astrocytes and other glial cells play a key role in the rearrangement of the neurovascular unit. They react to inflammatory stimuli by expressing chemokines (CXC and CC type) ([@B65]). The CCL20, expressed only by astrocytic cells, is essential for the recruitment of white cells to the CNS ([@B5]). The concentration of CCL22 is reduced in the damaged brain tissue and in the bloodstream following AIS and is associated with poor stroke outcome ([@B65]). The CCL22 receptor CCR4, expressed on Th2 cells can shift the inflammatory response toward an adaptive deregulation, suppressing Th1-polarized response. This is supportive for a protective immune response, initiated during the acute ischemic event and lasting for some time ([@B195]). Microglia express C1q during transient ischemic attack and deposits of C3d and C9 have been reported on neuronal cells after traumatic concussion ([@B151]; [@B172]; [@B175]). Depletion of the complement factor, C1q deficiency, and C1-inhibitor expression (Figure [1](#F1){ref-type="fig"}) are neuroprotective too, improving blood flow and neurological recovery after transient ischemia, and reducing the intracerebral edema following hemorrhage ([@B204]; [@B216]; [@B193]).

According to these data, complement levels in the cerebrospinal fluid (CSF) are elevated following AIS and correlate with BBB failure. C1q, C3b, and C3d have been found close to the ischemic penumbra ([@B101]; [@B153]; [@B175]). All these data show the putative role of complement activation in tissue recovering after AIS, thus offering new perspectives on the role of complement during the postictal plastic reorganization.

Thrombin effects depend on its concentration: the increase produces an adaptive-maladaptive gradient ([@B113]; [@B12]; [@B17]; [@B26]; [@B64]). Following AIS in the surrounding non-ischemic tissue, thrombin concentration is high; this could influences the recovery in the ischemic penumbra. In the PAR1 null animal model, a reduction of the ischemic area and repair in the postictal phase has been reported ([@B74]). Drug inhibition of PAR1, or its knockdown, restores the impaired synaptic plasticity and neurotransmission in hippocampal slices exposed to oxygen and glucose deprivation (OGD) ([@B185]). Thrombin is produced in the brain and its concentration alters the homeostatic behavior in both pathology and physiology ([@B17]). In OGD and transient medial cerebral artery occlusion (TMCAO) models, the levels of endogenous thrombin and FX are elevated; this affects synaptic function and alters the coagulation process ([@B26]; [@B97]; [@B185]). Thrombin in the perilesional area can be derived by the brain tissue itself or by the bloodstream following to BBB failure. However, how endogenous thrombin is involved in the AIS or ischemic chronic phase remains not completely understood.

One hypothesis is that impairment of inhibitory neurotransmission by γ-aminobutyric acid (GABA), or by increased paired-pulse facilitation (PPF) also known as neural facilitation, would partially account for post-ischemic epileptic seizure ([@B115], [@B111],[@B112]; [@B17]). PPF is reduced by the administration of PAR1 antagonist or diazepam (GABAergic drug) ([@B26]). PAR1 receptor sensitivity to different G proteins activation in different brain areas (or PAR1 partial activation) could be a good premise to explain the thrombin-dose related effects ([@B124]; [@B112]). Hence, thrombin should be considered at least one of the triggers of the stroke-dependent seizures. This is a real perspective to pursue a therapeutical PAR1 inhibitory approach to treat epilepsy, not necessarily related to stroke. In the paradigm of PAR1 partial activation, a potential target is aPC; it efficiently interferes with inflammation, by promoting vascular integrity and sustaining the neuronal cells viability, thus improving the post-ischemic outcome ([@B31]). We previously reported that BBB stability and endothelium integrity are mediated by aPC and PAR1 pathway ([@B45]); furthermore, the aPC improves synaptic plasticity during rehabilitation, probably through EPCR/PAR1/Sphingosine1-phosphate receptor1 (S1P1R) intracellular activation ([@B114]). S1P1R modulation with FTY720 (Fingolimod) receptor agonist, or with a novel more specific receptor agonist (RP101075) have shown to improve the clinical outcome of AIS and intracerebral hemorrhage (ICH) in animal models ([@B103]; [@B189]). Fingolimod, being approved as treatment for MS (for its immunosuppressive properties) reduce the capability of lymphocyte infiltration of CNS, reduce perilesional edema, preserve the neurovascular unit and polarize microglia toward the attenuated neuroinflammatory polarization through the STAT3 pathway ([@B189]; [@B158]).

A recent phase 2 clinical trial with Fingolimod in AIS has been completed^[2](#fn02){ref-type="fn"}^and another trial combinating Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) is ongoing^[3](#fn03){ref-type="fn"}^. Whether this mechanism involves neurons or astrocytes PAR response is still debated, however, the co-localization of EPCR and PAR1 in specific brain areas (as hypothesized), mainly in the hippocampus, has been shown ([@B114]). These reported data suggest that developing S1P1R agonists and thrombin inhibitors acting on PAR1 specific signaling, combined with the progress of thrombolytic therapies (or mechanical thrombectomy), will reduce both AIS lethality and post-ischemic hospitalization. Indeed, it is compelling to define the pathophysiology underlying the reparative processes of ischemic tissues and the perilesional area, having special attention to the neuro-immune coagulation pathways.

Alzheimer's Disease
===================

Alzheimer's disease (AD) is a degenerative, gradually progressive, irreversible form of cognitive degeneration, recognized as the most diffused type of dementia ([@B162]), and responsible for up to 60--80% of an estimated population (in 2010) of 35.6 million people worldwide affected by cognitive decay ([@B163]; [@B121]). Gaetano Perusini and Alois Alzheimer firstly described AD at the beginning of the 20th century ([@B110]) with their studies on AD anatomopathological hallmarks represented by amyloid-β (Aβ) plaques and neurofibrillary tangles (aggregates of hyperphosphorylated tau protein), cortical atrophy and gliosis ([@B149]; [@B162]). The classical phenotype of AD is called hippocampal type and is characterized by progressive and disabling loss of memory function, with an amnestic syndrome selectively compromising episodic memory during early stages ([@B51]). AD variant phenotypes include diseases affecting primary cognitive function other than memory, with apraxia, loss of visual identification or aphasia (respectively biparietal, occipitotemporal, or logopenic variant) ([@B51]). Advanced neuroimaging or biomarkers (mostly in the CSF) based on Aβ or tau proteins and genetic profiling searching for causative mutations of presenilin1/2 or amyloid-precursor protein (APP) and risk factors such as apolipoprotein-E ε4 allelic variant now facilitate clinical diagnosis ([@B51]). We need to find, as Perusini speculated, "\[...\] a noxious agent, which causes the whole disease, also acts on the blood vessels or equally damages both the neuron and the blood vessels" ([@B110]).

Platelets are pivotal and pleiotropic in the regulation of inflammation and repair processes. In AD they might play a role in the proteolytic processing of APP by carrying a disintegrin and metalloproteinase (ADAM)17 ([@B180]; [@B56]) or by favoring the complement cascade initiation. ADAM family proteins are transmembrane proteases that can perform the so-called α-cleavage on APP ([@B179]). A-cleavage prevents Aβ formation by inhibiting APP sequential cleavage by an aspartyl protease called BACE1 (β site APP cleaving enzyme 1) and by the γ-secretase with the following release of amyloid peptides of different lengths and aptitude for plaque formation (Aβ-38, Aβ-40, Aβ-42) ([@B179]). The link between AD and complement proteins has been proposed after the deposition of C proteins was shown inside Aβ plaques. Subsequently, it was reported that amyloid itself could activate the complement cascade, even without the involvement of antibodies (as pattern recognition of damaged-self) ([@B168]). This mechanism, overcoming the NIReg protective function, is functional in the general circulation, mediated by C3b and CR1 on erythrocytes. Furthermore, the genetic association between complement receptors or regulators (CR1 and clusterin) and AD has been suggested, opening the more vast scenario involving inflammatory regulators, lipid metabolism, complement, and platelets in the development of the disease ([@B83]). It has been demonstrated a coordinated involvement of clusterin, involved in complement-mediated cell lysis (also known as apolipoprotein j) (Figure [1](#F1){ref-type="fig"}), phospholipase-A2 (PLA2) and platelet-activating factor (PAF) ([@B146]; [@B83]; [@B169]). The deficit of the early stage complement factors (e.g., C3) in AD mouse models has been shown to increase deposits of Aβ and accelerate the disease progression, probably due to a neuroprotective role played by the complement in clearing the plaque in the early phases of their formation ([@B215]; [@B116]). These data must be considered with a caveat since the AD transgenic mouse model has been considered deficient in fully mimicking the human AD pathophysiology ([@B176]). However, the immune system, considering the toll-like receptors (TLRs) or nucleotide-binding oligomerization domain (NOD)-like receptors and cytokines release, seems to share a common network with immune cells, complement and coagulation cascade through the damage-associated molecular patterns (DAMPs) recognition ([@B168]).

Thrombin and the DAMP high-mobility group box protein 1 (HMGB1) have been associated to impaired memory formation acting cooperatively on the neuro-immune pathway, disrupting the neurovascular unit ([@B59]). HMGB1 in particular seems to act via TLR4 and the receptor for advanced glycation end product (RAGE) impairing memory in an animal model ([@B122]).

Chronic vasculopathies and hypoxic damage have been reported in AD patient, along with fibrin depots in both capillaries and large vessels without the typical ischemic stepladder progression of the vascular dementia ([@B123]). Besides the vascular hypo-perfusion and/or blood stasis, the fibrin deposition could play a signaling role in sustaining CNS inflammation and BBB failure, along with tight-junction digestion and ECM remodeling following blood cell invasion ([@B132]).

Considering Aβ deposition as a putative mechanism triggering the self-generating, self-sustaining degenerative process, and a DAMP itself prompting the immune system, Aβ-mediated expression of MMP-9 could alter the neurovascular unit and partially account for the intracerebral amyloid angiopathy (CAA) and the spontaneous parenchymal hemorrhages that almost constantly accompany disease progression ([@B75]). Thrombin and FXIIIa are constituents of Aβ deposits in the vessel walls in CAA, suggesting a local activation mediated by amyloid, while FXIIIa can also form complexes with Aβ (both Aβ-40 and Aβ-42 fragments) by a mechanism that is independent of the binding site employed during fibrin ligation, and Ca^2+^ dependent ([@B42]).

High thrombin concentration has a neurotoxic effect on microvessels of AD patient and can induce astrocytes apoptosis and BBB disruption followed by edema and blood leakage ([@B194]; [@B75]; [@B173]). Aβ-42 itself can be considered as a thrombin activating factor through FXI and FXII sequential activation, as shown in response to Aβ-42 oligomers ([@B219]). This process further involves C1 inhibitor that can block FXIa, FXIIa, and kallicrein, endorsing the integration of the neuro-immune hemostatic model ([@B219]). This thrombotic effect could be counterbalanced by soluble (s)APP expressing several Kunitz-type protease inhibitory domains, being able to block the protease functionality of coagulation factors at multiple levels ([@B16]). The sAPP is produced during the Aβ-42 formation with a substantial possible balance between activation/repression of hemostasis. However, accumulation of one of these two fragments in several areas of CNS and blood vessels can account for the spotty aspects of thrombosis and hemorrhage, thoroughly described in the pathophysiology of the AD ([@B160]). Protease nexin 1 (PN1) is a potent thrombin inhibitor released by glial cells that has been found extremely reduced and complexed with thrombin in AD patients, although its activity in Aβ depots was increased, probably due to the excess of thrombin ([@B205]; [@B8]). Thrombin effects in AD, however, seem to be essentially regulated by PAR-1 through Gi/phosphatidylinositol-3 kinase (PI3K) signaling ([@B206]) and MMP-9 upregulation to prompt pathological effects on cells, endothelium, and ECM ([@B98]). Furthermore, MMP-9 activity is induced by plasmin, which converts pro-MMP-9 to active MMP-9. In addition to its effect on other ECM components, MMP-9 is involved in the degradation of nerve growth factor (NGF), a neurotrophin essential for development and function of cholinergic and other NGF-responsive neurons ([@B39]; [@B32]). On the other hand, the tPA-plasmin system itself regulates the processing and maturation of pro-NGF and pro-BDNF to their corresponding mature forms ([@B96]; [@B148]; [@B23]; [@B34]). This implies that, in addition to the transcriptional events regulating neurotrophin levels ([@B35]), both thrombin and the tPA-plasmin system play a pivotal role in modulating neuronal differentiation and the structural changes linked to activity-dependent plasticity or Aβ toxicity.

Neoplastic Diseases
===================

Neoplasm developing inside the skull may be subdivided in primary lesions developing from resident cell clones (astrocytes, meninges, pituitary gland, bone or vascular structures, neurons or embryonic remnants) and secondary brain tumors, originating from systemic tumor metastasis, which are the most common ([@B46]). The primary lesions from lung, breast cancers account for the 75% of metastasis, while melanoma, testicular and renal carcinomas are rare, but most likely tend to metastasize to the brain ([@B63]). The overall incidence of all brain tumors worldwide is 25.48 cases per 100,000 person ([@B46]).

Several reports have shown a role of activated platelets in inflammatory chronic processes and metastatic cancer ([@B143]). Platelets in metastatic cancer patients change the expression of VEGF, PF4 and TSP-1 with increase of platelet number and marks of persistent activation ([@B212]). VEGF is increased, while PF and TSP-1 are reduced, raising multiple hypotheses for the differentially released mediators, the platelets protein scavenging function, or the modulation of the megakaryopoiesis (megakaryocyte maturation and subsequent platelet formation from the common hemopoietic stem cell) ([@B67]). It has been shown that platelet depletion, or the block of platelet surface receptors, decreases metastasis formation and tumor-platelets aggregates in animal models. This correlation between platelets and tumor metastasis is the shield hypothesis ([@B55]).

Embolization of tumor cells covered by platelets could be one of the ways for cancer spreading. Platelets may be an anchorage system by their subendothelial receptors and integrins (such as P-selectin, GPIb, αIIbβ3) to breakdown the neurovascular unit and defeat the ECM resistance through MMPs secretion, producing a shield against the immune system, releasing transforming growth factor beta (TGF-β) and inhibiting natural killer cell antitumor reactivity ([@B86]; [@B88]). Tumor cells can promote thrombocytosis by interfering with the megakaryocytopoiesis or by releasing unknown inflammatory cytokines ([@B57]). Cancer produces a well-known hypercoagulability state and thrombin can promote cancer growth and VEGF release supporting the vascular net growth in the expanding mass ([@B57]). Platelets factors also play intriguing roles in promoting metastasis and favoring angiogenesis through VEGF release. Although platelets express anti-angiogenic factor, such as TSP-1, PF4 and endostatin ([@B220]), they are the main serum sources of these mediators ([@B21]; [@B60]). In the recent years, extensive literature has been produced on the increase of these proteins in cancer, aiming to define whether it is specific of the early cancer stages or regulating tumor growth, however, the precise mechanism underlying metastasis and neuro-immune system crosslink remains to be explained ([@B143]). From this perspective, the C-type lectin-like receptor 2 (CLEC-2)A plays a key role in mediating tumor interactions; it binds to podoplanin, physiologically expressed on kidney podocytes and lymphatic endothelial cells, protecting the tumor from the immune system aggression and inducing platelet aggregation and tumor metastasis progression ([@B190]).

Gliomas are the most common primary CNS tumors ([@B107]). They are classified, by the World Health Organization (WHO), by their molecular markers, the biological activity and the histologic features, from grade I (non-malignant and slowly-growing associated with long-term survival) to grade IV (very aggressive malignant tumors, with fast-rate growing and short patient survival) ([@B156]; [@B107]). In adults, the glioblastoma multiforme (GBM) is the most frequent grade IV glioma characterized by highly infiltrative mass, with diffuse necrosis inside, highly infiltrative nature and whole brain diffusion, marked angiogenesis, apoptosis deregulation, and high genetic instability ([@B156]; [@B107]).

Thrombin levels into the lesion are very high, with a typical co-occurrence of thrombosis and hemorrhage that could in some extent favor the uncontrolled dissemination and growth of the malignant mass ([@B93]; [@B128]). The transduction-signaling pathway of thrombin, in these circumstances, is essentially by the canonical activation of PARs. Activation of PAR2, the lower affinity receptor, is possible, due to its high concentration found in brain tumor and following a vascular injury ([@B128]). The putative PARs transactivation and dimerization could affect several cell functions by multiple transduction signals, still unknown but a promising gateway to design new therapeutic strategies ([@B128]).

Tumor gene instability causing the development of cancer, whatever is the underlying mechanism or causative gene, leads to an altered cell proliferation/apoptosis ratio with the immortalization of a cellular clone. This process is, at final steps, regulated by mitogen activated protein kinases (MAPK), mainly extracellular signal--regulated kinase (ERK)1 and ERK2 ([@B141]; [@B27]). The intracellular transduction pathway seems to be cell-type related; however, the PI3K/PLC/PKC transduction can be considered as the key player ([@B208]). PAR1, is even in these circumstances the crucial thrombin receptor and its expression, well-investigated in metastatic tumor, seems to be correlated to the tumor grading and invasiveness ([@B221]), thus opening the research for future development of targeted chemotherapies ([@B87]). PARs can react with platelets beyond the tumor cells site. Platelets recognize also normal resident cells, not involved in the neoplastic process, and exert a neurotoxic effect on the healthy tissue, whereas tumor cells, expressing platelet receptors (mimicry phenomenon) can activate mitogenic pathways through the interaction between thrombin and PAR1-4 ([@B182]; [@B214]). Surprisingly thrombin, at the site of the lesion, may mediate a protective role in a concentration independent manner. The protease can process the esophageal cancer related gene 4 (Ecrg4) having a chemotactic property for myeloid cells and can activate a host-versus-cancer pro-inflammatory reaction, slowing tumor growth ([@B94]), hastening the neuro-immune response. Ecrg4 that could in principle be the switch between thrombin adaptive/maladaptive changes and a key node in the neuro-immune activation is indeed downregulated in the high grade gliomas ([@B71]).

Thrombin is involved in the persistent release of growth factors, as discussed for VEGF and tumor neo-angiogenesis ([@B77]). Fibrin, stabilized by FXIIIa is one of the proposed mechanism of the immunological masking ([@B207]). Kallicreins ([@B49]), and specifically kallicreins 6-7-9, are also associated with poor survival in patients with GMB. How these serine proteases directly promote tumor cell survival need to be revealed, however, kallicrein 6 induces resistance to radiation and chemotherapy (temozolomide) in glioma cells by a PAR1 dependent mechanism ([@B50], [@B49]).

The TF, the principal initiator of coagulation, is also upregulated in gliomas and perilesional tissues ([@B207]; [@B93]), hence being the activator of many thrombin-related toxic effects. Microglial activation has harmful effects on neurons and astrocytes ([@B222]) when exposed to high-level of thrombin and the reaction is characterized by intra and perilesional edema and altered leukocyte infiltration ([@B207]) or complement activation ([@B76]). The complement system has been historically correlated to the cancer destruction mediated by the innate immune system, but it has been reported that a component of the system can promote the growth of malignant tumors ([@B119]). The occurrence of C3 and C5b-9 complex depots in patients with GBM suggests the involvement of these proteins in the cancer process, even though serum level of complement system does not correlate with patient survival ([@B18]).

Psychiatric Diseases
====================

Mental health has many definitions. The WHO recognizes the "state of well-being" as the possibility to realize the person's potential, resilience to the normal life stressors and, based on the social nature of our species, it emphasizes that for mental health recognition a person should make a working contribution to the community ([@B118]). The absence of mental health, without detectable macroscopic organic lesion, is the domain of psychiatric diseases. The most treated and frequent disorders are unipolar depression, bipolar disorder, schizophrenia, and substance use disorders (addiction). Depression, expressed to a great extension among the population, is strictly related to blood coagulation disorders and complement activation ([@B196]; [@B41]). The incidence of this disease grows from the 5% of the population up to 20% in subjects following ischemic heart diseases; moreover, cardiovascular diseases represent an independent risk factor for major depression ([@B61]; [@B62]; [@B196]).

There are many variables to take into consideration when relating infarcts and depression. Obviously, scarce therapy compliance and negative habits (e.g., smoking, physical inactivity, dietary high calories intake) may influence both diseases; however, the role played by the underlying molecular pathways must be taken into account ([@B139]; [@B150]). A 20-year study has shown that men which were hostile and prone to anger or depression had a complement system hyper-activation with the increase of C3, that could favor an ischemic heart disease. The study results were standardized for age, alcohol intake, and body mass index (BMI) ([@B19]).

The relation between C3 increase and heart diseases has been confirmed in both myocardial infarctions and stable angina pectoris ([@B217]). In a mouse model of depression the levels of glial protein S100B and C3 has been found significantly lower in the amygdala, hippocampus, hypothalamus, prefrontal cortex, and striatum in control and after peripheral LPS administration ([@B188]). The role of C3 in the development of CNS has been studied in C3 deficient mice; they showed reduced immature synapse elimination and development of aberrant neuronal networks ([@B186]). In schizophrenic patients, in comparison to bipolar patients and healthy subjects, the C3 and C4 serum concentrations and their hemolytic properties were decreased ([@B183]). A pathway proteomic profile of ischemic stroke survivors with mild depression showed that both lectin and the classical pathway of complement activation are downregulated and the phenomenon is associated with depressive symptoms ([@B140]). C3 is pivotal for the entire process; it is required for both lectin and classical activation of complement and for immune system regulation.

Platelets are the putative intriguing link interlacing mental, immune system, and coagulation-related disorders. These elements pivotal in the coagulation and complement cascade are the main reservoir of systemic serotonin. Indeed, their hyperactivity could explain both ischemic and depressive disorders ([@B139]; [@B135]). Patients affected by major depressive disorder (MDD), matched with healthy subjects, showed increased platelet activation and expression of GPIIb-IIIa and P-selectin ([@B136]). Platelets BDNF-containing granules were decreased in MDD, which could account for the limbic cortical thickness reduction ([@B52]; [@B102]). Treatment with the Citalopram, a selective serotonin reuptake inhibitor (SSRI), normalized BDNF level. Additionally, a single nucleotide polymorphism (SNP) of BDNF has been frequently associated with MDD, bipolar disorder ([@B177]), and coronary heart disease ([@B20]). It has been reported that the physiological response of platelets to thrombin is increased in manic, compared to depressed or schizophrenic patients, via a PKC modulated pathway ([@B210]). Mental health disorders are generally associated to a pro-coagulatory activity showing fibrinolytic residues in the general circulation (this is partly reversed by the therapy) ([@B174]; [@B68]). The methylenetetrahydrofolate reductase (MTHFR) gene variant C677T, involved in the one-carbon metabolic pathway which is essential for DNA biosynthesis and the epigenetic process of DNA methylation, a cardiovascular and ischemic stroke independent risk factor, has been associated with schizophrenia, bipolar and unipolar depressive disorder ([@B154]; [@B54]).

Psychoactive drugs interact with the CNS reward system and cause a substance abuse disorder (also known as addiction) interfering with the fine neurotransmitters balance ([@B70]). Substance abuse disorder is a self-maintaining disorder with the dismal capacity of compulsive seeking repression, which overcome self-preserving mechanisms and the judgment of risk-taking ([@B79]). The social burden and the danger, deriving from the incapacity of measuring the negative outcome of actions, make addiction devastating, especially when it evolves in a chronic condition with the failure of the scarcely available treatments ([@B144]). Opiate abuse has been related to the deficiency of blood coagulation cascade with an increased fibrinolysis and higher levels of α2-macroglobulin ([@B29]). Morphine, methamphetamine, and nicotine increase the release of dopamine in the nucleus accumbens and activate post-synaptic dopamine receptors D1 (D1R). D1R activates cAMP/PKA pathway and extracellular enhancement of tPA activity in the nucleus accumbens that regulates dopamine release through PAR1 and is involved in the double mechanism of reward and dependence ([@B81]; [@B138]). Ethanol addiction and withdrawal further enhance tPA activity. This mechanism is not plasmin-PAR1 mediated, but it produces the overexpression of NR2B subunit of the *N*-methyl-[D]{.smallcaps}-aspartate receptor (NMDAR) without intermediate proteolytic activity. Ethanol could inhibit the glutamate receptor whose expression is compensatively increased, until a rapid decrease of ethanol levels relieves the inhibitory tone on the overexpressed NMDAR population, leading to withdrawal symptoms and even seizures ([@B152]; [@B138]).

Perspective
===========

Experimental and clinical reports unequivocally correlate the coagulation with the immune system and neuroinflammatory, degenerative, ischemic, proliferative, and functional disorders of the CNS. Platelet-derived, complement and clotting factors, CNS resident cells and protease intracellular signal transduction can modify the neurovascular unit integrity and recruit leukocytes at the site of the damage (Figure [2](#F2){ref-type="fig"}). Circulating coagulation proteins, complement and immune cells interact with several messengers and with each other to provide an active continuous scavenging activity, promptly correcting the structural or functional failures that constantly jeopardize the CNS homeostasis.

Central nervous system elements are partially protected by the immune privilege guaranteed by the BBB, through a constantly and actively filtering operated by endothelium, astrocytes, pericytes, and ECM. However, they express all the potential ligand and receptors to react actively to external damage. The chronicity of this reaction, mediated by both endogenous as exogenous elements can partly account for the switch between a remedial adaptive plasticity to the damage and a maladaptive rewiring of the CNS with disruption of synaptic stability and aberrant formation of newly deposed ECM. In the neuro-immune hemostasis framework concurring to CNS pathology, the coagulation and the immune system are cooperative in pathophysiological conditions, specifically after the BBB failure.

The analysis of literature data on cellular-protein-interactions involved in neuro-immune hemostasis allows designing a proposal for the main protein-hubs of this network formed by three fundamental nodes and one internode (Figure [3](#F3){ref-type="fig"}). The first node of the network is thrombin with activation of PAR-1 in a dose-dependent manner; the second node is C3, linking coagulation, synaptic plasticity and immune system; the third node is GPIb, essential for activated platelet anchorage, coagulation processes, thrombin activation and C3 activation. The internode is represented by αMβ2 integrin (part of the CR3) connecting the second and the third node of the network.

![Network analysis using the string.org platform for protein--protein interactions (PPIs) which integrates Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The databases query demonstrates the solid neuro-immune hemostatic network with the pivotal hubs strictly interconnected and the expandable hub-spoke associations. Four input proteins (F2, C3, ITGAM, GP1BA) with 14 nodes and 23 edges (minimum required interaction score: highest confidence 0.900; PP1 enrichment *p*-value of 0.00103). C3, complement component 3; CD, cluster of differentiation; CFH, complement factor H; CR1, complement component (3b/4b) receptor 1; FG, fibrinogen: alpha (FGA) or gamma (FGG) chain; F2, thrombin; F2R, protease-activated receptor-1 (PAR-1); ITGAM, integrin αM (C3 receptor 3 subunit); THBD, thrombomodulin; SERPINC1, serpin peptidase inhibitor, clade C member 1 (antithrombin III); SERPIND1, serpin peptidase inhibitor, clade D member 1 (heparan cofactor).](fncel-12-00459-g003){#F3}

To better understand how to favor the maintenance of the remedial adaptive plasticity, which would have a clear therapeutic interest for several pathological conditions, it would be useful to construct predictive molecular models, like the proposed network. The perspective is to be able to enlighten the regulating logic of the complex molecular network of Figure [3](#F3){ref-type="fig"}, which belongs to different cellular domains (neurons, astrocytes, BBB, and blood cells).

Several types of mathematical models have been described in the literature to analyze complex patho/physiological functions. The more immediate tool is offered by network analysis ([@B106]), which builds on protein--protein interaction map (PPI), performed at genome-wide level. For several diseases it has been reported where the nodes of the network under examination (in our case those of Figure [3](#F3){ref-type="fig"}) cluster on the general PPI map. In this way, it would be possible to ascertain which basic cellular functions interact with the cluster under investigation. It would be of interest, for instance, to know whether one of the nodes in Figure [3](#F3){ref-type="fig"} interacts with mitochondrial metabolism, autophagy or apoptosis.

Other possibilities are offered by dynamic systems biology models ([@B1]; [@B9]), whose computational analysis has been able to shed some light on the regulatory logic governing either inflammation response or T cell differentiation. It is expected that the interactions of computational models and new experiments, suggested by the model predictions, will be able to elucidate the fine structure of molecular events generated by blood coagulation and neuro-immune response in several CNS diseases, thereby opening the way to more effective treatments.
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